Hyperlipoproteinemia(a): Clinical significance and treatment options

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 1-5

  Berthold, Heiner K ^a   Gouni Berthold, Ioanna ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; EPROTIROME; EZETIMIBE; FIBRIC ACID DERIVATIVE; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID; RALOXIFENE; TIBOLONE;

APHERESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERANCE; EXERCISE; FEASIBILITY STUDY; FLUSHING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HEALTH CARE SYSTEM; HUMAN; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN APHERESIS; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; REIMBURSEMENT; SIDE EFFECT;

BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; HYPERLIPOPROTEINEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A); ODDS RATIO; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; UP-REGULATION;

EID: 84872869604     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.037     Document Type: Article

References (32)

1. Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 1963, 59:369-382.
2. Utermann G. The mysteries of lipoprotein(a). Science 1989, 246:904-910.
3. Hobbs H.H., White A.L. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 1999, 10:225-236.
4. Nielsen L.B., Juul K., Nordestgaard B.G. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler Thromb Vasc Biol 1998, 18:641-649.
5. Poon M., Zhang X., Dunsky K.G., Taubman M.B., Harpel P.C. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997, 96:2514-2519.
6. Boffa M.B., Marcovina S.M., Koschinsky M.L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004, 37:333-343.
7. Nielsen L.B., Gronholdt M.L., Schroeder T.V., Stender S., Nordestgaard B.G. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 1997, 17:905-911.
8. Bennet A., Di Angelantonio E., Erqou S., et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008, 168:598-608.
9. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102:1082-1085.
10. Craig W.Y., Neveux L.M., Palomaki G.E., Cleveland M.M., Haddow J.E. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998, 44:2301-2306.
11. Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
12. Erqou S., Kaptoge S., Perry P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
13. Kamstrup P.R., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008, 117:176-184.
14. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331-2339.
15. Clarke R., Peden J.F., Hopewell J.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518-2528.
16. Gouni-Berthold I., Berthold H.K. Lipoprotein(a): current perspectives. Curr Vasc Pharmacol 2011, 9:682-692.
17. Seed M., O'Connor B., Perombelon N., O'Donnell M., Reaveley D., Knight B.L. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993, 101:61-68.
18. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210:353-361.
19. Gouni-Berthold I., Berthold H.K. Antisense oligonucleotides for the treatment of dyslipidemia. Curr Pharm Des 2011, 17:950-960.
20. Cannon C.P., Shah S., Dansky H.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363:2406-2415.
21. Ladenson P.W., Kristensen J.D., Ridgway E.C., et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010, 362:906-916.
22. Berthold H.K., Laudes M., Krone W., Gouni-Berthold I. Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans. PLoS One 2011, 6:e24719.
23. Thompson G.R. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247-255.
24. Keller C. Apheresis in coronary heart disease with elevated Lp(a): a review of Lp(a) as a risk factor and its management. Ther Apher Dial 2007, 11:2-8.
25. Thompsen J., Thompson P.D. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006, 189:31-38.
26. Julius U., Frind A., Tselmin S., Kopprasch S., Poberschin I., Siegert G. Comparison of different LDL apheresis methods. Expert Rev Cardiovasc Ther 2008, 6:629-639.
27. Jaeger B.R., Richter Y., Nagel D., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009, 6:229-239.
28. Stefanutti C., Vivenzio A., Di Giacomo S., Mazzarella B., Ferraro P.M., Abbolito S. Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care. Transfus Apher Sci 2010, 42(1):21-26.
29. Kassner U., Vogt A., Rosada A., et al. Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). Atheroscler Suppl 2009, 10:85-88.
30. Thompson G.R. Lipoprotein apheresis. Curr Opin Lipidol 2010, 21:487-491.
31. Myers G.L., Christenson R.H., Cushman M., et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009, 55:378-384.
32. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007, 28:2375-2414.